MeSH term
Frequency | Condition_Probility | Adult | 9 | 0.0 |
Child | 5 | 0.0 |
Female | 48 | 0.0 |
Humans | 127 | 0.0 |
Male | 21 | 0.0 |
1-Phosphatidylinositol 3-Kinase/metabolism | 4 | 0.0 |
Breast Neoplasms/metabolism | 2 | 1.0 |
Enzyme Activation | 16 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Mitogen-Activated Protein Kinases/metabolism | 5 | 0.0 |
Receptor, erbB-2/*metabolism | 14 | 9.0 |
Research Support, U.S. Gov't, P.H.S. | 60 | 0.0 |
Tumor Cells, Cultured | 33 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Cell Division | 12 | 0.0 |
DNA Primers/chemistry | 3 | 0.0 |
Fibroblasts/metabolism | 3 | 0.0 |
Immunoblotting | 3 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Phosphorylation | 31 | 0.0 |
Polymerase Chain Reaction | 4 | 0.0 |
Receptor, erbB-2/genetics/*physiology | 2 | 28.0 |
Research Support, Non-U.S. Gov't | 96 | 0.0 |
Signal Transduction | 17 | 0.0 |
Tyrosine/metabolism | 8 | 0.0 |
Cell Line | 19 | 0.0 |
Dimerization | 7 | 0.0 |
Ligands | 24 | 0.0 |
Neuregulin-1/pharmacology | 2 | 13.0 |
Receptor, Epidermal Growth Factor/*metabolism | 23 | 2.0 |
Receptor, erbB-2/*physiology | 5 | 20.0 |
Receptor, erbB-3/*physiology | 2 | 40.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 15 | 0.0 |
Amino Acid Sequence | 29 | 0.0 |
Drug Design | 3 | 0.0 |
Kinetics | 7 | 0.0 |
Models, Molecular | 5 | 0.0 |
Molecular Sequence Data | 34 | 0.0 |
Protein Conformation | 3 | 0.0 |
Immunohistochemistry/methods | 6 | 0.0 |
Prognosis | 3 | 0.0 |
Receptor, erbB-2/*analysis | 2 | 2.0 |
Sequence Homology, Amino Acid | 16 | 0.0 |
Animals | 74 | 0.0 |
Blotting, Western | 9 | 0.0 |
Cell Survival | 2 | 0.0 |
Cells, Cultured | 15 | 0.0 |
Coculture Techniques | 2 | 0.0 |
Dose-Response Relationship, Drug | 3 | 0.0 |
Immunoprecipitation | 2 | 0.0 |
In Situ Nick-End Labeling | 3 | 0.0 |
Mice | 46 | 0.0 |
Neuregulin-1/*metabolism | 5 | 35.0 |
Proto-Oncogene Proteins/metabolism | 10 | 0.0 |
Rats | 21 | 0.0 |
Time Factors | 6 | 0.0 |
COS Cells | 5 | 0.0 |
Neuregulins/*metabolism | 2 | 50.0 |
Receptor, erbB-2/metabolism | 14 | 8.0 |
Receptor, erbB-3/genetics/*metabolism | 2 | 66.0 |
Aged | 8 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Down-Regulation | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 3 | 0.0 |
Immunohistochemistry | 9 | 0.0 |
Middle Aged | 7 | 0.0 |
RNA, Messenger/analysis | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 11 | 0.0 |
*ADP Ribose Transferases | 3 | 3.0 |
*Bacterial Toxins | 3 | 2.0 |
Binding, Competitive | 2 | 0.0 |
Mutation | 2 | 0.0 |
Phosphotyrosine/metabolism | 5 | 1.0 |
Protein Binding | 9 | 0.0 |
Protein Structure, Tertiary | 6 | 0.0 |
Receptor, Epidermal Growth Factor/metabolism | 17 | 3.0 |
Recombinant Proteins/metabolism | 5 | 0.0 |
*Virulence Factors | 3 | 3.0 |
Genes, erbB | 2 | 25.0 |
*Genes, erbB-2 | 3 | 3.0 |
Receptor, erbB-3 | 17 | 19.0 |
Structure-Activity Relationship | 2 | 0.0 |
Base Sequence | 13 | 0.0 |
DNA Primers | 6 | 0.0 |
Endopeptidases/*metabolism | 3 | 2.0 |
Membrane Proteins/*metabolism | 2 | 0.0 |
Protein Transport | 2 | 0.0 |
Receptor, Epidermal Growth Factor/chemistry/*metabolism | 3 | 8.0 |
Substrate Specificity | 4 | 0.0 |
Transfection | 11 | 0.0 |
Antineoplastic Agents/pharmacology | 2 | 0.0 |
Breast Neoplasms | 3 | 1.0 |
Cell Division/physiology | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 6 | 0.0 |
MAP Kinase Signaling System/*physiology | 2 | 2.0 |
Microscopy, Fluorescence | 4 | 0.0 |
Receptor, Epidermal Growth Factor/antagonists & inhibitors/*metabolism | 2 | 6.0 |
Receptor, erbB-2/genetics/*metabolism | 4 | 12.0 |
Recombinant Fusion Proteins/genetics/metabolism | 3 | 0.0 |
Antineoplastic Agents/*pharmacology/therapeutic use | 2 | 2.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Receptor, Epidermal Growth Factor/genetics/*metabolism | 9 | 5.0 |
Comparative Study | 13 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Receptor, Epidermal Growth Factor/analysis | 5 | 2.0 |
Receptor, erbB-2/analysis | 2 | 2.0 |
Cell Cycle | 2 | 0.0 |
Cell Line, Tumor | 5 | 0.0 |
Cloning, Molecular | 11 | 0.0 |
DNA, Complementary/metabolism | 4 | 0.0 |
Actins/metabolism | 2 | 0.0 |
Signal Transduction/physiology | 6 | 0.0 |
Tyrphostins/pharmacology | 2 | 1.0 |
Blotting, Northern | 6 | 0.0 |
Fluorescent Antibody Technique | 2 | 0.0 |
Heparin/metabolism | 3 | 2.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Mice, Knockout | 5 | 0.0 |
Quinazolines/pharmacology | 2 | 2.0 |
Tumor Cells, Cultured/drug effects/metabolism | 2 | 1.0 |
Gene Expression Regulation, Developmental | 3 | 0.0 |
Mammary Glands, Animal/*metabolism | 2 | 10.0 |
Signal Transduction/*physiology | 4 | 0.0 |
3T3 Cells | 2 | 0.0 |
Cell Membrane/metabolism | 2 | 0.0 |
Cell Movement/drug effects | 2 | 0.0 |
Gene Expression | 4 | 0.0 |
Signal Transduction/*drug effects | 2 | 0.0 |
Child, Preschool | 4 | 0.0 |
Protein Isoforms/biosynthesis/genetics | 2 | 3.0 |
*Protein-Serine-Threonine Kinases | 4 | 0.0 |
Solubility | 3 | 0.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 3 | 1.0 |
Proto-Oncogene Proteins/*metabolism | 4 | 0.0 |
*Signal Transduction | 9 | 0.0 |
Gene Expression Regulation | 5 | 0.0 |
Receptor, Epidermal Growth Factor/*genetics | 4 | 1.0 |
Precipitin Tests | 4 | 0.0 |
RNA, Messenger/metabolism | 9 | 0.0 |
Receptor, erbB-3/metabolism | 11 | 37.0 |
Tissue Distribution | 5 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Adolescent | 3 | 0.0 |
Cell Division/drug effects | 9 | 0.0 |
Immunoenzyme Techniques | 6 | 0.0 |
*Intercellular Signaling Peptides and Proteins | 6 | 1.0 |
Cell Movement/physiology | 3 | 1.0 |
Promoter Regions (Genetics) | 3 | 0.0 |
RNA, Messenger/biosynthesis/genetics | 2 | 0.0 |
Recombinant Proteins/pharmacology | 4 | 0.0 |
Up-Regulation | 4 | 0.0 |
Vascular Endothelial Growth Factor A | 2 | 0.0 |
Vascular Endothelial Growth Factors | 2 | 0.0 |
p38 Mitogen-Activated Protein Kinases | 4 | 0.0 |
Receptor, erbB-2/*genetics | 4 | 10.0 |
Breast Neoplasms/*pathology | 2 | 0.0 |
Central Nervous System Depressants/*pharmacology | 2 | 12.0 |
Ethanol/*pharmacology | 2 | 1.0 |
Receptor, Epidermal Growth Factor/biosynthesis/*metabolism | 2 | 9.0 |
Neoplasm Proteins/*metabolism | 2 | 0.0 |
Receptor Protein-Tyrosine Kinases/*metabolism | 3 | 1.0 |
Cell Differentiation | 4 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Phenotype | 2 | 0.0 |
Binding Sites | 7 | 0.0 |
Biological Transport | 2 | 0.0 |
CHO Cells | 3 | 0.0 |
Hamsters | 4 | 0.0 |
Protein Isoforms/genetics/metabolism | 2 | 1.0 |
Rabbits | 2 | 0.0 |
Breast Neoplasms/*metabolism | 5 | 1.0 |
Breast Neoplasms/*metabolism/pathology | 2 | 1.0 |
Cell Count/drug effects | 2 | 2.0 |
Culture Media, Serum-Free | 3 | 0.0 |
Neuregulin-1/metabolism | 4 | 30.0 |
Alternative Splicing | 2 | 0.0 |
Phosphorylation/drug effects | 4 | 0.0 |
Tumor Cells, Cultured/drug effects | 2 | 0.0 |
Cell Cycle/drug effects | 5 | 0.0 |
Reference Values | 2 | 0.0 |
Receptor, erbB-2/*biosynthesis | 2 | 4.0 |
Calcium/metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/chemistry/*metabolism | 2 | 3.0 |
Recombinant Proteins/chemistry/metabolism | 2 | 0.0 |
Sequence Alignment | 6 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Rats, Sprague-Dawley | 4 | 0.0 |
Schwann Cells/cytology/metabolism | 2 | 22.0 |
Bladder/cytology/*metabolism/pathology | 2 | 66.0 |
Epidermal Growth Factor/genetics/metabolism/*physiology | 2 | 40.0 |
Mice, Inbred Strains | 3 | 0.0 |
Mitogens/pharmacology | 3 | 1.0 |
Muscle, Smooth/cytology/*metabolism/pathology | 2 | 100.0 |
Urethral Obstruction/*metabolism/pathology | 2 | 100.0 |
Animals, Newborn | 3 | 0.0 |
Mice, Nude | 2 | 0.0 |
Receptor, Epidermal Growth Factor/*physiology | 3 | 2.0 |
Heart/*embryology | 2 | 3.0 |
Mice, Mutant Strains | 2 | 0.0 |
*Transcription Factors | 3 | 0.0 |
Mice, Transgenic | 7 | 0.0 |
Pregnancy | 5 | 0.0 |
src Homology Domains | 3 | 0.0 |
Species Specificity | 2 | 0.0 |
Cell Compartmentation/physiology | 2 | 5.0 |
Neuregulins | 15 | 26.0 |
1-Phosphatidylinositol 3-Kinase/*physiology | 2 | 3.0 |
Antineoplastic Agents/*pharmacology | 2 | 0.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/*physiology | 2 | 8.0 |
Epidermal Growth Factor/metabolism | 3 | 0.0 |
Glycoproteins/*pharmacology | 6 | 6.0 |
*Mitogen-Activated Protein Kinases | 3 | 0.0 |
Protein-Tyrosine Kinase/metabolism | 3 | 0.0 |
In Vitro | 4 | 0.0 |
*Intracellular Signaling Peptides and Proteins | 4 | 0.0 |
Macromolecular Substances | 3 | 0.0 |
Carrier Proteins/*pharmacology | 3 | 6.0 |
Mitogen-Activated Protein Kinase 3 | 3 | 0.0 |
*Neuregulin-1 | 11 | 42.0 |
Recombinant Proteins/genetics/metabolism | 2 | 0.0 |
Cell Survival/drug effects | 6 | 0.0 |
*Genes, erbB-1 | 2 | 11.0 |
Sensitivity and Specificity | 2 | 0.0 |
Proteoglycans | 2 | 2.0 |
Blotting, Southern | 2 | 0.0 |
Neoplasm Staging | 2 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 2 | 0.0 |
Carrier Proteins/*metabolism | 3 | 0.0 |
Glycoproteins/*metabolism | 4 | 2.0 |
RNA, Messenger/biosynthesis | 3 | 0.0 |
Receptor, erbB-2/genetics/metabolism | 2 | 13.0 |
Receptor, erbB-3/genetics/metabolism | 2 | 50.0 |
Reverse Transcriptase Polymerase Chain Reaction/methods | 2 | 0.0 |
Survival Rate | 2 | 0.0 |
Retinoblastoma Protein/metabolism | 2 | 0.0 |
Epidermal Growth Factor/pharmacology | 5 | 0.0 |
Transforming Growth Factor alpha/pharmacology | 2 | 2.0 |
Ca(2+)-Calmodulin Dependent Protein Kinase/metabolism | 3 | 0.0 |
Protein Structure, Secondary | 2 | 0.0 |
Epidermal Growth Factor/*metabolism | 3 | 0.0 |
Risk Factors | 2 | 0.0 |
Glycoproteins/genetics/metabolism | 2 | 8.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
Enzyme Activation/drug effects | 2 | 0.0 |
Transplantation, Heterologous | 3 | 0.0 |
Tyrosine | 2 | 1.0 |
DNA, Complementary/genetics | 2 | 0.0 |
In Situ Hybridization | 3 | 0.0 |
Chromosome Mapping | 2 | 0.0 |
Glycoproteins/*physiology | 2 | 3.0 |
*Protein Conformation | 2 | 0.0 |
Protein Folding | 2 | 0.0 |
Receptor, Epidermal Growth Factor/genetics/metabolism | 2 | 3.0 |
Proteins/metabolism | 2 | 0.0 |
Axons/physiology | 3 | 6.0 |
Receptor, Epidermal Growth Factor/*biosynthesis | 2 | 1.0 |
Neoplasm Transplantation | 2 | 0.0 |
Gene Expression Profiling | 2 | 0.0 |
Receptor, erbB-2/biosynthesis/*genetics | 2 | 28.0 |
Antineoplastic Agents/pharmacology/therapeutic use | 2 | 6.0 |
Models, Biological | 2 | 0.0 |
Green Fluorescent Proteins | 2 | 0.0 |
Receptor, Epidermal Growth Factor/genetics | 2 | 1.0 |
Caseins/genetics | 2 | 18.0 |
DNA-Binding Proteins/genetics/*metabolism | 2 | 0.0 |
Gene Deletion | 2 | 0.0 |
Trans-Activators/genetics/*metabolism | 2 | 0.0 |
Mitogen-Activated Protein Kinase 1/metabolism | 2 | 0.0 |
Up-Regulation/drug effects | 2 | 0.0 |
Crystallography, X-Ray | 2 | 0.0 |
Disease Models, Animal | 2 | 0.0 |
